Premium
Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases
Author(s) -
Wang Kai,
Zhu ZhiJun,
Zheng Hong,
Deng YongLin,
Pan Cheng,
Sun LiYing,
Shen ZhongYang
Publication year - 2012
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2011.00926.x
Subject(s) - hbsag , medicine , hbeag , ascites , hepatitis b , liver transplantation , gastroenterology , lamivudine , hepatitis b virus , antibody , immunology , transplantation , virus
Aim: The aim of this study is to identify the titres of protective hepatitis B surface antibodies (anti‐HBs) in the blood and their effective factors in the early stage after liver transplantation (LT) for hepatitis B virus (HBV) related diseases. The condition of anti‐HBs lost in ascites fluid was also investigated. Methods: Twenty‐six patients who received LT were administered prophylaxis of lamivudine combining intravenous hepatitis B immunoglobulin (HBIG) post‐LT. The titres of anti‐HBs were recorded and analyzed daily in blood and ascites fluid within the first week post‐LT. Results: In the first 5 days post‐LT, the titres of anti‐HBs in HBV DNA positive groups, high hepatitis B surface antigen (HBsAg) groups, hepatitis B e antigen (HBeAg) positive groups were lower than that in the parallel HBV DNA negative groups, low HBsAg groups and HBeAg negative groups. The mean titre level of anti‐HBs in ascites fluid is 224.89 IU/L and fluctuated from 0.00 IU/L to 968.50 IU/L, which is also correlated with anti‐HBs titres in blood drawn at the same time ( r = 0.927, P = 0.000). The level of anit‐HBs in ascites fluid was very high; however, it fluctuated in a wide range (from 0.00 IU to 908.55 IU). Conclusions: Patients in high risk groups should receive a higher level of HBIG to maintain sufficient amounts of anti‐HBs in the early stage post‐LT, while the patients in low risk groups need a lower level of HBIG administration. Furthermore, the lost amount of anti‐HBs in ascitic fluid post‐LT has minimum impact on the anti‐HBs titres in blood.